Go Pro

Artivion (AORT) Insider Trading & Ownership

Artivion logo
$25.40 -0.18 (-0.68%)
As of 03:10 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Artivion (NYSE:AORT) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
6.30%
Number Of
Insiders Buying
(Last 12 Months)
0
Number Of
Insiders Selling
(Last 12 Months)
8
Amount Of
Insider Selling
(Last 12 Months)
$18.77M
Get AORT Insider Trade Alerts

Want to know when executives and insiders are buying or selling Artivion stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AORT Insider Buying and Selling by Quarter

Artivion Insider and Congressional Trades History

Transaction DateInsiderBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/3/2026Sell1,493$26.02$38,847.86  
9/2/2026Sell6,510$27.27$177,527.70  
8/19/2026Sell70,000$28.95$2,026,500.00  
8/12/2026Sell977$28.49$27,834.73  
6/11/2026Sell44,001$20.70$910,820.70  
3/4/2026Sell8,962$38.00$340,556.00  
3/3/2026Sell901$37.78$34,039.78  
3/3/2026Sell17,887$37.78$675,770.86  
3/3/2026Sell3,843$37.78$145,188.54  
3/3/2026Sell4,573$37.78$172,767.94  
3/3/2026Sell6,316$37.78$238,618.48  
3/3/2026Sell2,149$37.78$81,189.22  
3/2/2026Sell641$38.02$24,370.82  
3/2/2026Sell14,911$38.02$566,916.22  
3/2/2026Sell2,183$38.02$82,997.66  
3/2/2026Sell2,784$38.02$105,847.68  
3/2/2026Sell5,178$38.02$196,867.56  
3/2/2026Sell1,513$38.02$57,524.26  
2/24/2026Sell830$35.69$29,622.70  
2/24/2026Sell13,936$35.69$497,375.84  
2/24/2026Sell1,668$35.69$59,530.92  
2/24/2026Sell2,075$35.69$74,056.75  
2/24/2026Sell4,485$35.69$160,069.65  
2/24/2026Sell1,259$35.69$44,933.71  
2/23/2026Sell1,731$37.59$65,068.29  
2/23/2026Sell20,962$37.59$787,961.58  
2/23/2026Sell3,079$37.59$115,739.61  
2/23/2026Sell3,773$37.59$141,827.07  
2/23/2026Sell4,981$37.59$187,235.79  
2/23/2026Sell2,423$37.59$91,080.57  
12/8/2025Sell4,572$44.42$203,088.24  
12/3/2025Sell7,315$45.30$331,369.50  
12/2/2025Sell30,921$45.56$1,408,760.76  
11/21/2025Sell47,376$45.04$2,133,815.04  
11/20/2025Sell15,276$44.18$674,893.68  
11/18/2025Sell4,200$45.10$189,420.00  
11/17/2025Sell6,000$45.73$274,380.00  
11/17/2025Sell6,394$45.17$288,816.98  
11/17/2025Sell6,394$45.17$288,816.98  
11/14/2025Sell6,393$45.00$287,685.00  
Moderna’s 177% Surge Puts Cancer Biotech Back in Focus (Ad)

Moderna shares surged 177% in a single trading session on August 19, adding about $45 billion in market value after Moderna and Merck reported positive Phase 3 results for an experimental melanoma treatment. GT Biopharma is taking a different approach, using an immunotherapy platform that harnesses Natural Killer cells against cancer without requiring a custom therapy for every patient. Its first-generation TriKE produced bone marrow blast level reductions of up to 63.7%, and preclinical data show a redesigned second-generation version up to 10-40x more potent, with two candidates now in Phase 1 trials.tc pixel

See why this microcap biotech could be nearing a defining moment
11/14/2025Sell6,393$44.67$285,575.31  
11/13/2025Sell3,482$45.86$159,684.52  
11/13/2025Sell34,210$45.86$1,568,870.60  
11/13/2025Sell5,761$45.86$264,199.46  
11/13/2025Sell6,563$45.86$300,979.18  
11/13/2025Sell4,993$45.86$228,978.98  
11/11/2025Sell10,000$46.18$461,800.00  
11/10/2025Sell1,789$44.62$79,825.18  
11/10/2025Sell17,580$44.62$784,419.60  
11/10/2025Sell2,960$44.62$132,075.20  
11/10/2025Sell3,373$44.62$150,503.26  
11/10/2025Sell2,566$44.62$114,494.92  
(Data available from 1/1/2013 forward)

AORT Insider Trading Activity - Frequently Asked Questions

6.30% of Artivion stock is owned by insiders. Learn more on AORT's insider holdings.

The following insiders have sold AORT shares in the last 24 months: Amy Horton ($1,323,895.07), Andrew M Green ($1,355,736.26), Anthony B Semedo ($74,022.00), Elizabeth A Hoff ($189,420.00), James P Mackin ($9,996,855.82), Jean F Holloway ($5,353,737.49), John E Davis ($2,524,949.18), Lance A Berry ($871,794.77), and Marshall S Stanton ($5,721,031.70).

Insiders have sold a total of 761,593 Artivion shares in the last 24 months for a total of $27,411,442.29 sold.

Gilbert Ray Cisneros, Jr. (D-CA) has sold shares of Artivion in the last year totaling $8,000.



This page (NYSE:AORT) was last updated on 9/8/2026 by MarketBeat.com Staff.
From Our Partners